Skip to main content

Table 5 Adverse effects and pathological findings indicators

From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project

INDICATORS ICO-B ICO-G ICO H IPO NO WCO All  
N
(%)
N
(%)
N
(%)
N
(%)
N
(%)
N
(%)
N % P
Post-surgery ypT 33
(82.5)
36
(90.0)
40
(100.0)
33
(84.6)
16
(72.7)
38
(95.0)
196 88.7 0.013
Post-surgery ypN 34
(85.0)
36
(90.0)
38
(95.0)
33
(84.6)
16
(72.7)
38
(95.0)
195 88.2 0.086
Patients with adjuvant treatment – chemotherapy 28
(70.0)
35
(87.5)
27
(67.5)
28
(71.8)
8
(36.4)
20
(50.0)
146 66.1 0.000
SIDE EFFECTS (≥ grade 3)
Acute (<  6 mo)
Rectitis 4
(10.0)
1
(2.5)
0
(0.0)
0
(0.0)
1
(4.5)
2
(5.0)
8 3.6 0.153
Cystitis-urethritis 0
(0.0)
0
(0.0)
1
(2.5)
0
(0.0)
0
(0.0)
0
(0.0)
1 0.5 0.474
Neutropenia 5
(12.5)
0
(0.0)
0
(0.0)
2
(5.1)
0
(0.0)
0
(0.0)
7 3.2 0.006
Diarrhea 0
(0.0)
4
(10.0)
3
(7.5)
1
(2.6)
1
(4.5)
2
(5.0)
11 5.0 0.385
Chronic (>  6 mo)
Rectitis 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0 0.0
Cystitis-urethritis 0
(0.0)
1
(2.5)
2
(5.0)
0
(0.0)
0
(0.0)
0
(0.0)
3 1.4 0.279
Neutropenia 1
(2.5)
2
(5.0)
3
(7.5)
1
(2.6)
0
(0.0)
0
(0.0)
7 3.2 0.414
Diarrhea 3
(7.5)
0
(0.0)
3
(7.5)
2
(5.1)
0
(0.0)
0
(0.0)
8 3.6 0.184